Globalisation and blood safety

References 

1. New Zealand Ministry of Foreign Affairs and Trade. Globalisation. <http://www.mfat.govt.nz/support/tplu/tradematters/glossary.html>; 2004 [accessed 18.04.06].
2. Wikipedia – The free encyclopaedia. Definition of globalisation. <http://en.wikipedia.org/wiki/Globalisation>; 2006 [accessed 18.04.06].
3. Fisher W. The role of WIPO in addressing the health crisis in developing countries. Presented to the trans atlantic consumer dialogue; 2004. <www.tacd.org/events/wipo/w_fisher.ppt>.
4. WHO World Health Report. <http://www.who.int/whr/2003/en/whr03_en.pdf>; 2003 [accessed 22.04.06].
5. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002;359:2188–2194
   • Abstract
   • Full Text
   • Full-Text PDF (106 KB)
   • CrossRef
6. European Federation of Pharmaceutical Industries and Associations. The pharmaceutical industry in figures. Brussels: EFPIA. <http://www.efpia.org>; 2000 [accessed 22.04.06].
7. Hubbard T, Love J. A new trade framework for global healthcare R&D. PLoS Biology 2004;2:0147–0150. <http://biology.plosjournals.org/archive/1545-7885/2/2/pdf/10.1371_journal.pbio.0020052-L.pdf>; [accessed 22.04.06].
8. Mattar MA. Blood and you. Health & science and alternative medicine 9-06-2004. <http://www.islamonline.net/english/science/2004/06/article04.shtml>; [accessed 22.04.06].
9. World Health Organization. Global database for blood safety-report. <http://www.who.int/bloodsafety/GDBS_Report_2001-2002.pdf>; 2001–2002 [accessed 22.04.06].
10. Snyder EL, Dodd RY. Reducing the risk of blood transfusion. Hematology Am Soc Hematol Educ Prog. 2001;433–442
11. Seed CR, Cheng A, Davis TM, Bolton WV, Keller AJ, Kitchen A, et al. The efficacy of a malarial antibody enzyme immunoassay for establishing the reinstatement status of blood donors potentially exposed to malaria. Vox Sang. 2005;88:98–106
    • MEDLINE
    • CrossRef
12. Center for Biologics Evaluation and Research. Issue summary – deferral of blood and plasma donors for history of transfusion in European countries. Transmissible Spongiform Encephalopathies Advisory Committee meeting; February 8, 2005. <http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4088B1_03.htm>; [accessed 22.04.06].
13. Yasser Arafat donates blood at Shifa hospital in Gaza City the day following the World Trade Center bombing. <http://www.jewishjournal.com/home/preview.php?id=13262> [accessed 22.04.06].
14. Kaplan EH. Israel’s ban on use of Ethiopians’ blood: how many infectious donations were prevented?. Lancet. 1998;351:1127–1128
    • Full Text
    • Full-Text PDF (45 KB)
    • CrossRef
15. Siegel J. Blood donations drop significantly. Jerusalem Post. 1996;6:12
16. Emmanuel J. cited in Farrugia A. On top, down Under. The Source 2002;5–11.
17. Farrugia A, Robert P. Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol. 2006;19:243–258
    • Abstract
    • Full Text
    • Full-Text PDF (174 KB)
    • CrossRef
18. MacGregor K, Fleck F. Scandal of HIV blood sold as safe by South Africans. <http://www.whale.to/v/blood1.html>; 2000 [accessed 22.04.06].
19. See the proceedings of the World Federation of Hemophilia’s fourth global forum on the safety and supply of treatments for bleeding disorders (World Federation of Hemophilia 2005) p. 25. <http://www.wfh.org/2/docs/Publications/Global_Forum/GF_Proceedings_2005_LOW_RES.pdf> [accessed 22.04.06].
20. European Commission. Directive 2002/98/EC of the European parliament and of the council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending directive 2001/83/EC. <http://europa.eu.int/eur-lex/pri/en/oj/dat/2003/l_033/l_03320030208en00300040.pdf>.
21. Side letter to the USA–Australia free trade agreement. <http://www.dfat.gov.au/trade/negotiations/us_fta/final-text/letters/02_blood_plasma_rev.pdf>; 2004 [accessed 22.04.06].

22. Clause 6 in Ref. [21].
23. Love J, Tubbard T. Make drugs affordable: replace TRIPs-plus by R&D-plus. Bridges. 2004;8:3–5
24. O’Neill K. A vital fluid: risk, controversy and the politics of blood donation in the era of “mad cow disease”. Public Understand Sci. 2003;12:359–380
25. Kimball AM, Arima Y, Hodges JR. Trade related infections: farther, faster, quieter. Globalization Health. 2005;1(3):1–6<http://www.globalizationandhealth.com/content/1/1/3>
26. Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion. 2003;438:1023–1028
27. Dodd R. Emerging infections and global blood safety. Dev Biol (Basel). 2007;127:237–248
    • MEDLINE
28. Murphy WG. Disease transmission by blood products: past, present and future. Pathophysiol Haemost Thromb. 2002;32(Suppl. 1):1–4
    • CrossRef
29. The origin of AIDS and HIV and the first cases of AIDS. <http://www.avert.org/origins.htm> [accessed 17.07.08].
30. UK review of the origin of BSE. UK Government. <http://www.defra.gov.uk/animalh/Bse/publications/bseorigin.pdf>; 2001 [accessed 17.07.08].
31. Petersen LR. The movement of West Nile virus in North America. <www.journalism.berkeley.edu/conf/disease/prez/petersen-w.nile.ppt> [accessed 17.07.08].
32. Epstein PR. Is global warming harmful to health?. Sci Am. 2000;(August):50–57
33. DeMaria A. The globalization of infectious diseases: questions posed by the behavioural, social, economic and environmental context of emerging infections. New Eng J Int’l Comp L. 2004;11(1):37–58
34. Related articles, LinksYu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet. 1995;345(8958):1173–1174
    • CrossRef
35. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–1239
    • CrossRef
36. Dhingra N. SARS as an emerging pathogen: SARS as an emerging pathogen: implications for blood safety. Presented to the WHO global conference on severe acute respiratory syndrome (SARS) 17–18 June 2003. <http://www.who.int/csr/sars/conference/june_2003/materials/presentations/bloodsafety180603.pdf> [accessed 22.04.06].
37. European parliament resolution on blood safety in the European Union. <http://www.europarl.europa.eu/pv2/pv2?PRG=CALDOC&FILE=950714&LANGUE=EN&TPV=DEF&LASTCHAP=6&SDOCTA=13&TXTLST=1&Type_Doc=FIRST&POS=1>; 1995 [accessed 17.07.08].
38. Napoleoni L. The new economy of terror 2004. <http://opendemocracy.net/content/articles/PDF/2321.pdf>.
39. United States general accounting office. Maintaining an adequate blood supply is key to emergency preparedness. <http://www.gao.gov/new.items/d021095t.pdf>; 2002 [accessed 22.04.06].
40. Glynn SA, Busch MP, Schreiber GB, Murphy EL, Wright DJ, Tu Y, et al. NHLBI REDS Study Group. Effect of a national disaster on blood supply and safety: the September 11 experience. JAMA. 2003;289(17):2246–2253
    • MEDLINE
    • CrossRef
41. World health organisation. Mission of the global collaboration for blood safety. <http://www.who.int/bloodsafety/gcbs/mission/en/>; 2004 [accessed 22.04.06].